Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them?

BACKGROUND: The UK Medicines Health products Regulation Agency instructs that valproate prescriptions should be restricted in women of childbearing age to those consenting to the Pregnancy Prevention Programme (PPP). We assessed the compliance and barriers to the valproate PPP. METHODS: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Watila, Musa Mamman, James, Alistair, Milne, Karen, Mackay, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357668/
https://www.ncbi.nlm.nih.gov/pubmed/37483432
http://dx.doi.org/10.1136/bmjno-2023-000433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357668/
https://www.ncbi.nlm.nih.gov/pubmed/37483432
http://dx.doi.org/10.1136/bmjno-2023-000433

Ejemplares similares